Trial Profile
A dose finding, pharmacokinetic and safety study of a recombinant human plasminogen activator (HTU-PA) [human tissue urokinase type plasminogen activator] in patients with acute ischemic stroke
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Human tissue urokinase-type plasminogen activator (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Sponsors Global Biotech
- 18 Jan 2007 New trial record.